Dr Mohd Arif Mohd Zim is a Consultant Respiratory Physician and Internal Medicine and is now Head, Discipline of Respiratory PPPUiTM. He graduated from Trinity College Dublin in 2002. He completed his Senior House Officer training in General Medicine for 2 years in Ireland. He pursued his post graduate training in Malaysia and obtained his Masters in Internal Medicine in University of Malaya in 2010. He joined UiTM as a Senior Lecturer in Internal Medicine in 2010. He completed his Fellowship in Respiratory Medicine in 2014.

He is a member of Malaysian Thoracic Society (MTS) and Sleep Disorder Society Malaysia (SDSM). His main interests are Respiratory Infection and Interventional Pulmonology.

Research:

CQMF149F2202 Study

A randomized, double-blind, 12-week treatment, parallel group study to evaluate the efficacy and safety of QMF149 (150 μg/160 μg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 μg/500 μg b.i.d.) in patients with chronic obstructive pulmonary disease

Risk factors for recurrent exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

SAS 115359 Study

A safety and efficacy study of inhaled Fluticasone Propionate/Salmeterol combination versus inhaled

Fluticasone Propionate in the treatment of adolescent and adult subjects with persistent asthma

BREATH 3085 Study

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0mg/kg) as Treatment for Patients with Eosinophilic Asthma Who Completed a Prior Cephalon-Sponsored Study in Eosinophilic Asthma

RESPOND Study

A 52-week, double blind, randomized, placebo controlled parallel group study to evaluate the effect of Roflumilast 500µg on exacerbation rate in subjects with chronic obstructive pulmonary disease (COPD) treated with a fixed dose combination of long-acting beta agonist and inhaled corticosteroid (LABA/ICS)

A Phase III, multicenter, international, randomised, parallel group, double blind cardiovascular safety study of BI10773 (10mg and 25mg administered once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk

A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat® Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler®

BREATH 3082 Study

A 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations and change in lung function in patients (12-75 years of age) with eosinophilic asthma

Publication

M.A Mohd Zim et al 2013, Chikungunya infection in Malaysia: Comparison with dengue infection in adults and predictors of persistent arthralgia. Journal of Clinical Virology, volume 56, issue 2 :141-145

AI Ismail,MA Aripin, MA Mohd Zim 2012, Rate of Lung Function Decline in Rural Urban Study of Malaysian Population. Respirology, 17(Suppl. 2): 123

AI Ismail,MA Mohd Zim,TS Tengku Ismail 2012, Cardiometabolic Co-Morbidities in Patients with OSA Attending Multidisciplinary Sleep Clinic. Respirology, 17(Suppl. 2): 119

MA Abd Rahman, NS Bakar,MA Mohd Zim, AI Ismail 2012, Clinical Correlation of EGFR Protein Overexpression with Histological Growth Pattern: A Preliminary Pattern. Respirology, 17(Suppl. 2): 97

Hazlyna Baharuddin,MA Mohd Zim,R Azmillah 2012,Tuberculosis Infection in patients with systemic lupus erythematosus in Malaysia.International Journal of Rheumatic Diseases 2012;15(Suppl.1):84